Pharmaceutical - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 751 results

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

TG Therapeutics takes up option on PI3K-Delta inhibitor, TGR-1202

23-09-2014

US development stage company TG Therapeutics says it has exercised its option to license the global rights…

HematologyLicensingOncologyPharmaceuticalRhizen PharmaceuticalsTG TherapeuticsTGR-1202

Merck & Co out-licenses tildrakizumab to Sun Pharma

Merck & Co out-licenses tildrakizumab to Sun Pharma

17-09-2014

US pharma giant Merck & Co has entered into an exclusive worldwide licensing agreement with Indian drugmaker…

DermatologicalsGlobalLicensingMerck & CoPharmaceuticalSun Pharmaceuticalstildrakizumab

Sanofi and MyoKardia ink deal for genetic heart disease research

Sanofi and MyoKardia ink deal for genetic heart disease research

17-09-2014

French pharma major Sanofi has signed a global collaboration with privately-held US firm MyoKardia to…

Cardio-vascularGlobalLicensingMyoKardiaPharmaceuticalResearchSanofi

Plethora signs licensing agreement with Recordati for premature ejaculation drug

Plethora signs licensing agreement with Recordati for premature ejaculation drug

16-09-2014

Urological specialist Plethora Solutions has signed a licensing agreement with international pharma group…

EuropeLicensingMen's HealthPharmaceuticalPlethoraPSD502Recordati

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

FDA accepts Tuzistra XR NDA for full review

FDA accepts Tuzistra XR NDA for full review

15-09-2014

The US Food and Drug Administration has confirmed that the New Drug Application for Tuzistra XR, a prescription…

LicensingPharmaceuticalRegulationRespiratory and PulmonaryTris PharmaTuzistraUSAVernalis

Akashi gets rights to novel DMD treatment from Tonus

Akashi gets rights to novel DMD treatment from Tonus

15-09-2014

US clinical-stage biopharma firm Akashi Therapeutics has acquired global rights to GsMTx-4, a small molecule…

Akashi TherapeuticsGlobalGsMTx-4LicensingPharmaceuticalRare diseasesTonus Therapeutics

Palatin licenses certain rights to Richter for bremelanotide

11-09-2014

USA-based Palatin Technologies and Hungary’s largest drugmaker Gedeon Richter have entered into a collaboration…

EuropeGedeon RichterLicensingPalatin TechnologiesPharmaceuticalWomen's Health

Norgine sells certain rights for Camcolit and Somnite to Essential Pharma

11-09-2014

Netherlands-headquartered independent drugmaker Norgine has agreed to sell all rights in the UK for Somnite…

Essential PharmaIrelandLicensingNeurologicalNorginePharmaceuticalUK

Meiji and Takeda to co-promote Rozerem for insomnia

Meiji and Takeda to co-promote Rozerem for insomnia

08-09-2014

Fellow Japanese drugmakers Meiji Seika Pharma and Takeda Pharmaceutical have finalized a co-promotion…

JapanLicensingMeiji Seika PharmaNeurologicalPharmaceuticalRozeremTakeda Pharmaceutical

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

Sellas Life Sciences gains WT1 cancer vaccine rights from Memorial Sloan Kettering

05-09-2014

Swiss/Greek pharmaceutical and clinical research group Sellas Life Sciences Group has signed an exclusive…

GlobalLicensingOncologyPharmaceuticalSellas Life SciencesVaccines

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

03-09-2014

US drug discovery firm Infinity Pharmaceuticals has entered into a global collaboration with AbbVie to…

AbbVieduvelisibInfinity PharmaceuticalsIPI-145LicensingOncologyPharmaceutical

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

Ablynx out-licenses ozoralizumab for Greater China to Eddingpharm

01-09-2014

Belgian drug developer Ablynx has expanded its relationship with China’s Eddingpharm, by granting the…

AblynxAnti-Arthritics/RheumaticsChinaEddingpharmLicensingMarkets & MarketingozoralizumabPharmaceutical

Chugai and Roche amend business arrangements on out-licensing

Chugai and Roche amend business arrangements on out-licensing

31-08-2014

Japanese drugmaker Chugai has amended the business arrangements with its majority (62%) share-owner Swiss…

Asia-PacificChugai PharmaceuticalEuropeLicensingPharmaceuticalRoche

Daiichi Sankyo links with Kaketsuken for Bimmugen sales

28-08-2014

Japanese drug major Daiichi Sankyo has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic…

Anti-viralsBimmugenDaiichi SankyoJapanKaketsukenLicensingMarkets & MarketingPharmaceuticalVaccines

Brazilian antitrust agency approves Bionovis and Merck's partnership deal

Brazilian antitrust agency approves Bionovis and Merck's partnership deal

28-08-2014

The General Superintendent of the Brazilian Antitrust Agency (CADE) approved the agreement between the…

BionovisBiosimilarsBrazilLicensingMerck KGaAPharmaceuticalResearch

Vivus acquires topiramate patents from Janssen

Vivus acquires topiramate patents from Janssen

26-08-2014

USA-based pharma company Vivus has acquired a group of patents from Johnson & Johnson’s Janssen Pharmaceuticals…

AnorecticsEuropean Medicines AgencyJanssen PharmaceuticaLicensingObesityPharmaceuticalPhentermine/topiramateQsymiaTopiramateUSAVivus

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

20-08-2014

UK-based Clinigen Group has acquired the global rights to the oncology support therapy Ethyol (amifostine)…

ClinigenClinigen GroupEthyolLicensingOncologyPharmaceuticalTreatment for head and neck cancerUK

Provectus opens negotiations on licensing PV-10 in China

Provectus opens negotiations on licensing PV-10 in China

19-08-2014

US developmental stage company Provectus Biopharmaceuticals has entered into a memorandum of understanding…

Breast cancerChinaLicensingMemorandum of understandingOncologyPharmaceuticalProvectus BiopharmaceuticalsPV-10Sinopharm

Photocure and Salix terminate Lumacan partnership

Photocure and Salix terminate Lumacan partnership

18-08-2014

Norwegian photodynamic technologies specialist Photocure has agreed to terminate the global licensing…

Cosmo PharmaceuticalsLicensingLumacanNorwayOncologyPharmaceuticalPhotocurePhotodynamic technologies specialistSalix PharmaceuticalsUSA

Eisai teams up with Zeria on proton pump inhibitor license agreement

Eisai teams up with Zeria on proton pump inhibitor license agreement

18-08-2014

Japanese drug major Eisai has collaborated with fellow Japanese company Zeria Pharmaceutical to conclude…

EisaiGastro-intestinalsJapanLicensingPharmaceuticalProton pump inhibitorsZeria Pharmaceuticals

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

China’s ZAI Lab in-licenses two respiratory drugs from Sanofi

14-08-2014

China-based ZAI Lab has obtained global rights for two novel compounds from French pharma major Sanofi,…

Chronic lower respiratory diseasesGlobalLicensingPharmaceuticalRespiratory and PulmonarySanofiZAI Lab

1 to 25 of 751 results

Back to top